Examining the Effect of ALK and EGFR Mutations on Survival Outcomes in Surgical Lung Brain Metastasis Patients

Area of Science:

• Oncology
• Genetics
• Neurology

Background:

• Targeted therapies like monoclonal antibodies (mAbs) and tyrosine-kinase inhibitors (TKIs) are crucial in post-genomic cancer treatment.
• Lung brain metastases (BMs) present unique challenges, with limited research on mutation-specific survival post-surgery.
• Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations are key targets in lung carcinoma.

Purpose of the Study:

• To investigate the impact of EGFR-amplified and ALK-rearranged mutations on survival in lung carcinoma patients with surgically treated brain metastases.
• To evaluate the efficacy of targeted therapies in this patient cohort.

Main Methods:

• Multi-site retrospective analysis of 95 lung carcinoma patients who underwent surgical resection for brain metastases (January 2012 - May 2022).
• Determination of mutational status (EGFR, ALK) from brain tissue biopsies.
• Survival analyses, including overall survival and progression-free survival, were conducted.

Main Results:

• EGFR-amplified mutations were found in 20.0% and ALK-rearranged mutations in 6.3% of patients.
• These specific mutations did not show a significant correlation with overall survival.
• Despite a limited sample size for targeted therapy recipients, improved overall and progression-free survival rates were observed compared to previous studies.

Conclusions:

• EGFR and ALK mutations alone may not be direct predictors of survival in lung brain metastasis patients undergoing surgery.
• Advancements in systemic treatment for lung metastases, including targeted therapies, are contributing to improved survival outcomes.
• The emergence of novel targeted therapies holds promise for enhancing survival and progression-free survival in lung brain metastasis patients.